LDL-C – Medxy AI

Aggressive LDL-C Lowering Mitigates Neoatherosclerosis Risk: Insights from the CONNECT Trial

By MedXY 12/24/2025

This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of aggressive lipid management in secondary prevention.

Cardiology news

Oral PCSK9 Inhibitor Enlicitide Produces ~58% LDL‑C Reduction in Heterozygous Familial Hypercholesterolemia: A Phase 3 Randomized Trial

By MedXY 11/10/2025

In adults with heterozygous familial hypercholesterolemia on statin therapy, oral enlicitide decanoate reduced LDL‑C by ~58% at 24 weeks versus placebo and was well tolerated through 52 weeks.

Cardiology Specialties

Inclisiran Shows Promise for Adolescents with Homozygous Familial Hypercholesterolemia: Results from the ORION-13 Trial

By MedXY 08/17/2025

The ORION-13 trial demonstrates that inclisiran significantly lowers LDL cholesterol by 33.3% and is safe and well tolerated in adolescents with homozygous familial hypercholesterolemia, addressing an unmet pediatric treatment need.